Wei‐Hsin Lin - Concepedia

Author

Wei‐Hsin Lin

National Taiwan University Hospital ORCID

Also Known As

W-H Lin, W. Lin, Wei-Hsin Lin, Wei‐Hsin Lin

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

National Taiwan University Hospital National Taiwan University Massachusetts General Hospital National Tsing Hua University Far Eastern Memorial Hospital

About

Wei‐Hsin Lin is an author at National Taiwan University Hospital specializing in medicine, oncology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	368
2	Health Sciences	4	4	113
3	Biostatistics	2	2	64
4	Cell Biology	2	2	138
5	Health Informatics	1	1	32

Wei‐Hsin Lin

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Treatment of Unicameral Bone Cyst Hsien-Yang Hou, Karl Wu, Chen‐Ti Wang, Journal of Bone and Joint Surgery	2010	263
STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis Wei‐Hsin Lin, Yi-Wen Chang, Min-Xiang Hong, Oncogene	2020	172
Artery and vein separation using susceptibility-dependent phase in contrast-enhanced MRA Y. Wang, Yingjian Yu, D. Li, Journal of Magnetic Resonance Imaging	2000	150
SFRPs Are Biphasic Modulators of Wnt-Signaling-Elicited Cancer Stem Cell Properties beyond Extracellular Control Chi-Jung Liang, Zih-Wun Wang, Yi-Wen Chang, Cell Reports	2019	115
Diverse Targets of β-Catenin during the Epithelial–Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse Yi‐Wen Chang, Ying-Jhen Su, Michael Hsiao, Cancer Research Cancer Stem CellStem Cell BiologyCancer BiologyTumor BiologyTranscriptional Regulation	2015	84
Valproic acid resensitizes cisplatin‐resistant ovarian cancer cells Ching‐Tai Lin, Hung‐Cheng Lai, Hsin‐Yi Lee, Cancer Science	2008	78
An aberrant nuclear localization of E-cadherin is a potent inhibitor of Wnt/β-catenin-elicited promotion of the cancer stem cell phenotype Y-J Su, Yi‐Wen Chang, Wei‐Hsin Lin, Oncogenesis	2015	76
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC Federico Cappuzzo, Michael McCleod, Maen Hussein, Annals of Oncology Progression-free SurvivalAdvanced Non-squamous NsclcMedicinePharmacologyImmune Checkpoint Inhibitor	2018	58
Similar Local Control between Phenol- and Ethanol-treated Giant Cell Tumors of Bone Wei‐Hsin Lin, Tsung-Yu Lan, Chih-Yu Chen, Clinical Orthopaedics and Related Research	2011	54
Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties Ying-Jhen Su, Wei‐Hsin Lin, Yi‐Wen Chang, Oncotarget Cancer Stem CellPathologyStem Cell MigrationCancer BiologyTumor Biology	2015	54

Page 1